Patent SG-11201805157T-A (SG)
Title: Targeted disruption of the mhc cell receptor
Inventor: LEE GARY K
IPC: C07K14/725
Filed: 2016-12-15
Abstract: WO 17 / 1065 37 A2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106537 A2 22 June 2017 (22.06.2017) WI PO I PCT (51) International Patent Classification: Not classified (21) International Application Number: PCT/US2016/066988 (22) International Filing Date: 15 December 2016 (15.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/269,410 18 December 2015 (18.12.2015) US 62/305,097 8 March 2016 (08.03.2016) US 62/329,439 29 April 2016 (29.04.2016) US (71) Applicant: SANGAMO BIOSCIENCES, INC. [US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). (72) Inventors: LEE, Gary K.; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). PASCHON, David; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). ZHANG, Lei; c/o Sangamo BioSciences, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). (74) Agent: PASTERNAK, Dahna; Pasternak Patent Law, 1900 Embarcadero Rd., Suite 211, Palo Alto, California 94303 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (54) Title: TARGETED DISRUPTION OF THE MHC CELL RECEPTOR Exon 1 og agATGTCT CGC C C GT 3GCCT TA ,CTGT GCTC:GCGC:l'ACTC CTCTTI:.:TU..: :T , :JAGGC ,'ATCCAGC Exon 2 GTAC —, CAAAGAT T ,- :ACI;TTTACTCACGTCATCCAGCAGAGAATGGAAAG TCAAATT TCCTGAATTGC - ':A.AATTTrTC4( - 4 GT T TCAT C CAT CC GACAT T GAAGT T GA GAATGGAGAGA AASTGGAGCAT TCAGACT TGT CT G TTCAGCAA( :ACT TCT T TCTATCTCT TGTACTACACTGAAT T CACCCCCACT 3AAAAAGATGAGTA:3CCTGCCGTG TGAACCATGTEACTTTGT , I., \"ACAGCCCAAGATAGTTAAGTGGE FIG. 1 (57) : Disclosed herein are methods and compositions for inactivating MHC genes, using zinc fmger nucleases (ZFNs) comprising a zinc fmger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Poly- nucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. 1111111111111101110101011111010111110 010110111111101101111111111111111110111111 E